Personalis to be acquired by Tempus for $16.25 per share
Personalis agreed to be acquired by Tempus for $1.5 billion, combining Tempus' commercial platform with Personalis' residual disease technology to advance cancer monitoring.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day